<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pharmacologic agents and colonic ischemia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pharmacologic agents and colonic ischemia</h1>
<div class="graphic"><div class="figure"><div class="ttl">Pharmacologic agents and colonic ischemia</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup width="50%"></colgroup><colgroup width="30%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug</td> <td class="subtitle1">Evidence</td> <td class="subtitle1">Postulated pathogenesis</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Moderate evidence</td> </tr> <tr> <td class="indent1">Constipation-inducing drugs</td> <td> <ul> <li>Predicted CI in patients with abdominal pain: 2.8 (1.1-7.1)<sup>[1]</sup> </li> <li>All drugs C-CS: Risk, 0.68 (0.62-1.27)<sup>[2]</sup> </li> <li>Opioids C-CS: Increased risk, 1.96 (1.43-2.67)<sup>[3]</sup> </li> <li>Nonopioids C-CS: Increased risk, 1.75 (1.25-2.44)<sup>[3]</sup> </li> </ul> </td> <td>Reduced blood flow, increased intraluminal pressure<sup>[4]</sup></td> </tr> <tr> <td class="indent1">Immunomodulator drugs</td> <td> <ul> <li>Antitumor necrosis factor-alpha inhibitors for rheumatoid arthritis from US FDA AERS: 17 probable, 18 possible cases; median age, 62 years*<sup>[5]</sup> </li> <li>Type 1 interferon: <ul> <li>Alpha for hepatitis C: 13 probable, 4 possible cases; median age, 51 years* </li> <li>11 other reported cases<sup>[6]</sup> </li> <li>Beta for multiple sclerosis: 19 probable, 20 possible cases; median age, 56 years </li> <li>10 other reported cases of interferon for hepatitis C (8 cases with age &lt;55 years)<sup>[7]</sup> </li> </ul> </li> </ul> </td> <td>Cytokines affecting thrombogenesis<sup>[8]</sup></td> </tr> <tr class="divider_bottom"> <td class="indent1">Illicit drugs</td> <td> <ul> <li>Amphetamines: 5 reported cases; age 42 to 50 years<sup>[8,9]</sup> </li> <li>Cocaine: Used by 19 of 97 (20%) CI patients at two inner-city hospitals; age 44 to 56 years; 37% right-sided and 16% small bowel disease; 26% mortality<sup>[10]</sup> </li> <li>Many other reported cases of multiple ischemic organs<sup>[8]</sup> </li> </ul> </td> <td>Vasoconstriction, hypercoagulation, direct endothelial injury<sup>[8]</sup></td> </tr> <tr> <td class="subtitle2_left" colspan="3">Low evidence</td> </tr> <tr> <td class="indent1">Antibiotics</td> <td> <ul> <li>Antibiotic-associated colitis resembles CI, usually right-sided<sup>[8]</sup><br/> C-CS: Increased risk, 3.3 (2.19-4.96)<sup>[3]</sup> </li> </ul> </td> <td>Altered gut microbiome (eg, <em>Klebsiella oxytoca</em>)<sup>[11]</sup></td> </tr> <tr> <td class="indent1">Appetite suppressants</td> <td> <ul> <li>Bitter orange (resembles ephedra): 1 reported case<sup>[12]</sup> </li> <li>Hydroxycut: 1 probable case*<sup>[13]</sup> </li> <li>Ma huang (mainly ephedrine): 1 reported case<sup>[14]</sup> </li> <li>Phentermine: 2 reported cases (1 with fenfluramine)<sup>[8,15]</sup> </li> <li>Xenadrine (bitter orange, ma huang, caffeine, salicin): 1 reported case<sup>[16]</sup> </li> </ul> </td> <td>Vasoconstriction<sup>[8]</sup></td> </tr> <tr> <td class="indent1">Chemotherapeutic drugs</td> <td> <ul> <li>R-CHOP: 1 reported case<sup>[17]</sup> </li> <li>Taxanes: 10 reported cases<sup>[8,18-20]</sup> </li> <li>Vinorelbine/cisplatin: 1 reported case<sup>[8]</sup> </li> <li>C-CS: Increased use of taxanes or vinca alkaloids on univariate analysis<sup>[3]</sup> </li> </ul> </td> <td>Direct epithelial toxicity, inhibited repair of vascular injury<sup>[8]</sup></td> </tr> <tr> <td class="indent1">Decongestants</td> <td> <ul> <li>Pseudoephedrine: 9 reported cases (6 cases with age &lt;50 years)<sup>[8,21]</sup><br/> C-CS: Risk unaffected, 1.1 (0.3-3.9)<sup>[22]</sup> </li> <li>Phenylephrine: 1 reported case<sup>[23]</sup> </li> </ul> </td> <td>Vasoconstriction<sup>[8]</sup></td> </tr> <tr> <td class="indent1">Diuretics</td> <td> <ul> <li>C-CS: Increased risk, 1.6 (1.2-2.1)<sup>[22]</sup> </li> </ul> </td> <td>Extracellular volume deficit, lower peripheral vascular resistance, vasoconstriction<sup>[8]</sup></td> </tr> <tr> <td class="indent1">Ergot alkaloids (often combined with caffeine)</td> <td> <ul> <li>20 reported cases<sup>[8,24]</sup> </li> </ul> </td> <td>Vasoconstriction<sup>[8]</sup></td> </tr> <tr> <td class="indent1">Hormonal therapies</td> <td> <ul> <li>Predominance of women among young patients<sup>[25,26]</sup>, common use of female hormones by female patients<sup>[27]</sup> </li> <li>Female hormones C-CS: Increased risk, 1.88 (1.30-2.73)<sup>[3]</sup> </li> <li>Oral contraceptives C-CS: Increased risk, 1.05 (1.00-1.10)<sup>[28]</sup>; risk unaffected, 0.59 (0.28-1.33)<sup>[29]</sup>; 0.7 (0.3-1.5)<sup>[22]</sup> </li> <li>Estrogen replacement C-CS: Risk unaffected, 0.75 (0.67-1.19)<sup>[29]</sup>; 1.0 (0.7-1.5)<sup>[22]</sup> </li> </ul> </td> <td>Hypercoagulability, endothelial injury<sup>[8]</sup></td> </tr> <tr> <td class="indent1">Laxatives</td> <td> <ul> <li>Osmotic agents: 2 reported cases<sup>[8]</sup> </li> <li>Bisacodyl: 2 reported cases<sup>[8]</sup> </li> <li>Bisacodyl/polyethylene glycol: 1 reported case of 2 episodes<sup>[30]</sup> </li> <li>Lubiprostone: 1 reported case<sup>[31]</sup> </li> <li>All drugs C-CS: Increased risk, 4.73 (3.71-6.02)<sup>[28]</sup> </li> </ul> </td> <td>Increased motility or rapid intravascular volume deficit, reduced perfusion<sup>[8]</sup></td> </tr> <tr> <td class="indent1">Psychotropic drugs</td> <td> <ul> <li>6 reported cases (2 with hypotension)<sup>[8,32,33]</sup> </li> <li>10 cases, clinical/pathological data incomplete<sup>[34]</sup> </li> <li>C-CS: Increased risk, 3.7 (1.3-11.0)<sup>[22]</sup> </li> </ul> </td> <td>Hypotension, constipation</td> </tr> <tr class="divider_bottom"> <td class="indent1">Serotoninergic drugs</td> <td> <ul> <li>5-hydroxytryptamine1 receptor agonists: 12 cases from US FDA AERS (8 cases with age &lt;50 years)<sup>[8,35-37]</sup> </li> <li>5-hydroxytryptamine3 receptor antagonist: 1 case of CI/1000 patient-years of use<sup>[38]</sup> </li> <li>5-hydroxytryptamine4 partial agonist: 27 reported cases (drug withdrawn)<sup>[39]</sup> </li> </ul> </td> <td>For 5-hydroxytryptamine1 receptor agonists vasoconstriction<sup>[8]</sup>; for other agents various factors<sup>[39]</sup></td> </tr> <tr> <td class="subtitle2_left" colspan="3">Very low evidence</td> </tr> <tr> <td class="indent1">Digitalis</td> <td> <ul> <li>1 reported case (poisoning)<sup>[8]</sup> </li> <li>Digoxin C-CS: Increased risk, 3.6 (2.1-6.2)<sup>[22]</sup>; atrial fibrillation not analyzed; decreased risk, 0.27 (0.083-0.86)<sup>[40]</sup> </li> </ul> </td> <td>Vasoconstriction</td> </tr> <tr> <td class="indent1">Kayexalate</td> <td> <ul> <li>1 reported case<sup>[41]</sup> </li> <li>44 cases of colon injury with incomplete pathological data<sup>[42]</sup> </li> </ul> </td> <td>Direct toxic effect, various non-drug factors<sup>[41,42]</sup></td> </tr> <tr> <td class="indent1">NO-Xplode</td> <td> <ul> <li>1 reported case<sup>[43]</sup> </li> </ul> </td> <td>Blood shunting to skeletal muscle, hypoperfusion, various non-drug factors<sup>[43]</sup></td> </tr> <tr> <td class="indent1">NSAIDs</td> <td> <ul> <li>Reported cases not clearly distinguishable from NSAID-induced colopathy<sup>[8]</sup> </li> <li>C-CS: Risk unaffected, 0.9 (0.6-1.2)<sup>[22]</sup>; 0.68 (0.62-1.27)<sup>[44]</sup> </li> </ul> </td> <td>Inhibition of vasodilating prostaglandins, vasoconstriction<sup>[8]</sup></td> </tr> <tr> <td class="indent1">Statins</td> <td> <ul> <li>2 reported cases<sup>[8,45]</sup> </li> </ul> </td> <td>None</td> </tr> <tr> <td class="indent1">Vasopressors</td> <td> <ul> <li>1 reported case<sup>[8]</sup> </li> </ul> </td> <td>Vasoconstriction</td> </tr> </tbody></table></div><div class="graphic_lgnd">The table provides the pharmacologic agents associated with colonic ischemia. Nonpharmacologic etiologies for colonic ischemia are presented in a separate table.</div><div class="graphic_footnotes">CI: colon ischemia; C-CS: case-control study (followed by odds ratio [95% confidence interval]); US FDA AERS: United States Food and Drug Administration Adverse Event Reporting System; R-CHOP: rituximab, cyclophosphamide, vincristine, doxorubicin, prednisolone; NSAID: nonsteroidal anti-inflammatory drug.<br/>* Classified by the criteria of Naranjo et al.<sup>[13]</sup></div><div class="graphic_reference">References: 

<ol>
<li>Park CJ, Jang MK, Shin WG, et al. Can we predict the development of ischemic colitis among patients with lower abdominal pain? Dis Colon Rectum 2007; 50:232.</li>
<li>Walker A, Bohn R, Cali C, et al. Risk factors for colon ischemia. Am J Gastroenterol 2004; 99:1333.</li>
<li>Longstreth GF, Yao JF. Diseases and drugs that increase risk of acute large bowel ischemia. Clin Gastroenterol Hepatol 2010; 8:49.</li>
<li>Boley SJ, Agrawal GP, Warren AR, et al. Pathophysiologic effects of bowel distention on intestinal blood flow. Am J Surg 1969; 117:228.</li>
<li>Salk A, Stobaugh DJ, Deepak P, et al. Ischaemic colitis in rheumatoid arthritis patients receiving tumour necrosis factor-alpha inhibitors: An analysis of reports to the US FDA Adverse Event Reporting System. Drug Saf 2013; 36:329.</li>
<li>Salk A, Stobaugh DJ, Deepak P, Ehrenpreis ED. Ischemic colitis with type I interferons used in the treatment of hepatitis C and multiple sclerosis: An evaluation from the food and drug administration adverse event reporting system and review of the literature. Ann Pharmacother 2013; 47:537.</li>
<li>Baik SJ, Kim TH, Yoo K, et al. Ischemic colitis during interferon-ribavirin therapy for chronic hepatitis C: A case report. World J Gastroenterol 2012; 18:4233.</li>
<li>Hass D, Kozuch P, Brandt L. Pharmacologically mediated colon ischemia. Am J Gastroenterol 2007; 102:1765.</li>
<li>Holubar SD, Hassinger JP, Dozois EJ, Masuoka HC. Methamphetamine colitis: A rare case of ischemic colitis in a young patient. Arch Surg 2009; 144:780.</li>
<li>Elramah M, Einstein M, Mori N, Vakil N. High mortality of cocaine-related ischemic colitis: A hybrid cohort/case-control study. Gastrointest Endosc 2012; 75:1226.</li>
<li>Hogenauer C, Langner C, Beubler E, et al. Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis. N Engl J Med 2006; 355:2418.</li>
<li>Sultan S, Spector J, Mitchell RM. Ischemic colitis associated with use of a bitter orange-containing dietary weight-loss supplement. Mayo Clin Proc 2006; 81:1630.</li>
<li>Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30:239.</li>
<li>Song HJ, Shim KN, Ryu KH, et al. A case of ischemic colitis associated with the herbal food supplement ma huang. Yonsei Med J 2008; 49:496.</li>
<li>Schembre DB, Boynton KK. Appetite-suppressant drugs and primary pulmonary hypertension. N Engl J Med 1997; 336:510.</li>
<li>Ryan CK, Reamy B, Rochester JA. Ischemic colitis associated with herbal product use in a young woman. J Am Board Fam Pract 2002; 15:309.</li>
<li>Halm U, Sack S, Zachaus M. Chemotherapy-induced ischemic colitis in a patient with jejunal lymphoma. Case Rep Gastroenterol 2010; 4:465.</li>
<li>Sodhi KS, Aiyappan SK, Singh G, et al. Colitis and colonic perforation in a patient with breast carcinoma treated with taxane based chemotherapy. Indian J Cancer 2011; 48:134.</li>
<li>Hussein MA, Bird BR, O'Sullivan MJ, et al. Symptoms in cancer patients and an unusual tumor: Case 2. Docetaxel-related ischemic colitis. J Clin Oncol 2005; 23:9424.</li>
<li>Carrion AF, Hosein PJ, Cooper EM, et al. Severe colitis associated with docetaxel use: A report of four cases. World J Gastrointest Oncol 2010; 2:390.</li>
<li>Sherid M, Samo S, Husein H, et al. Pseudoephedrine-induced ischemic colitis: Case report and literature review. J Dig Dis 2014; 15:276.</li>
<li>Yadav S, Dave M, Varayil JE, et al. A population-based study of incidence, risk factors, clinical spectrum, and outcomes of ischemic colitis. Clin Gastroenterol Hepatol 2014; 13:731.</li>
<li>Ward PW, Shaneyfelt TM, Roan RM. Acute ischaemic colitis associated with oral phenylephrine decongestant use. BMJ Case Rep 2014.</li>
<li>Rodman RE, Willson TD, Connolly MM, Podbielski FJ. Ischemic colitis secondary to ergotamine use: A case study. Case Rep Gastroenterol 2011; 5:1.</li>
<li>Longstreth GF, Yao JF. Epidemiology, clinical features, high-risk factors, and outcome of acute large bowel ischemia. Clin Gastroenterol Hepatol 2009; 7:1075.</li>
<li>Deana D, Dean P. Reversible ischemic colitis in young women. Association with oral contraceptive use. Am J Surg Pathol 1995; 19:454.</li>
<li>Newman JR, Cooper MA. Lower gastrointestinal bleeding and ischemic colitis. Can J Gastroenterol 2002; 16:597.</li>
<li>Chang L, Kahler KH, Sarawate C, et al. Assessment of potential risk factors associated with ischaemic colitis. Neurogastroenterol Motil 2008; 20:36.</li>
<li>Walker A, Bohn R, Cali C, et al. Risk factors for colon ischemia. Am J Gastroenterol 2004; 99:1333.</li>
<li>Baudet JS, Castro V, Redondo I. Recurrent ischemic colitis induced by colonoscopy bowel lavage. Am J Gastroenterol 2010; 105:700.</li>
<li>Sherid M, Sifuentes H, Samo S, et al. Lubiprostone induced ischemic colitis. World J Gastroenterol 2013; 19:299.</li>
<li>Shah V, Anderson J. Clozapine-induced ischaemic colitis. BMJ Case Rep 2013.</li>
<li>Tsesmeli NE, Savopoulos ChG, Koliouskas DP, et al. Colonic toxicity of antidepressants: An unusual case of a 48-year-old patient with transient ischemic colitis. Int J Colorectal Dis 2007; 22:985.</li>
<li>Peyriere H, Roux C, Ferard C, et al. Antipsychotics-induced ischaemic colitis and gastrointestinal necrosis: A review of the French pharmacovigilance database. Pharmacoepidemiol Drug Saf 2009; 18:948.</li>
<li>Hodge JA, Hodge KD. Ischemic colitis related to sumatriptan overuse. J Am Board Fam Med 2010; 23:124.</li>
<li>Moawad FJ, Goldkind L. An unusual case of colonic ischemia. South Med J 2009; 102:405.</li>
<li>Nguyen TQ, Lewis JH. Sumatriptan-associated ischemic colitis: Case report and review of the literature and FAERS. Drug Saf 2014; 37:109.</li>
<li>Michael H, Brandt LJ, Hochsztein JG. Ischemic colitis complicating aortic dissection. Gastrointest Endosc 2002; 55:442.</li>
<li>Lewis JH. The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies. Drug Saf 2011; 34:545.</li>
<li>Cubiella Fernandez J, Nunez Calvo L, Gonzalez Vazquez E, et al. Risk factors associated with the development of ischemic colitis. World J Gastroenterol 2010; 16:4564.</li>
<li>Tapia C, Schneider T, Manz M. From hyperkalemia to ischemic colitis: A resinous way. Clin Gastroenterol Hepatol 2009; 7:e46.</li>
<li>Harel Z, Harel S, Shah PS, et al. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: A systematic review. Am J Med 2013; 126:264.</li>
<li>Magee CD, Moawad FJ, Moses F. NO-Xplode: A case of supplement-associated ischemic colitis. Mil Med 2010; 175:202.</li>
<li>Walker AM, Bohn RL, Cali C, et al. Risk factors for colon ischemia. Am J Gastroenterol 2004; 99:1333.</li>
<li>Tan J, Pretorius CF, Flanagan PV, Pais A. Adverse drug reaction: Rosuvastatin as a cause for ischaemic colitis in a 64-year-old woman. BMJ Case Rep 2012.</li></ol>Adapted by permission from Macmillan Publishers Ltd: American Journal of Gastroenterology. Brandt LJ, Feuerstadt P, Longstreth GF, et al. ACG clinical guideline: Epidemiology, risk factors, patterns of presentation, diagnosis, and management of colon ischemia (CI). Am J Gastroenterol 2015; 110:18. Copyright © 2015. <a href="http://www.nature.com/ajg" target="_blank">www.nature.com/ajg</a>.</div><div id="graphicVersion">Graphic 115263 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
